Abstract 1689TiP
Background
One of the unmet needs in Lung Cancer Care is the Stigma of patients due to the smoking habits; the condition of current smoker or former smoker causes the perception of the one’s incorrect lifestyle so, more than in other pathologies, patients with lung cancer are burdened with feelings of guilt and self-devaluation in anticipation of a negative social judgment. In addition to detecting this phenomenon, the study aims to psychologically support lung cancer patients, as well as smokers who belong to the Antismoking Centre in our Institute and who present with high levels of distress, through a psychotherapeutic path according to the EMDR (Eye Movement Desensitization and Reprocessing) model which could allow the reworking of traumatic or emotionally stressful moments, linked to the phases of the disease and to the personal history. The EMDR is one of the techniques that support smokers in quitting; the processing of the experience that occurs with EMDR allows the subject, through desensitization and cognitive restructuring, to change perspective and adopt more appropriate behaviors.
Trial design
Objectives of this study are the following: 1) to document the presence of stigma in current smokers or former smokers with lung cancer and subjects who undertake a smoke cessation program ; 2) to measure the correlation between stigma, level of anxiety, depression, quality of life and psychophysical well-being in the different phases of the disease starting from diagnosis and throughout treatment process;3) to investigate the impact and the efficacy of the EMDR model through the psychological re-evaluation of stress, depression and anxiety. The sociocultural, psychological factors and lifestyles of the participants will be investigated, including any gender-related differences regarding the Lung Cancer stigma, smoking habits and the outcome of a tobacco cessation process. A number of 45 subjects is planned to be recruited.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1646P - A multicohort phase II trial of androgen deprivation therapy (ADT), docetaxel (DOCE) and nivolumab (NIVO) in patients (pts) with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) enriched for inflamed tumours and DNA damage repair (DDR) alterations: Cohort 3 results
Presenter: Xiao Wei
Session: Poster session 11
1647P - Clinical validity of plasma DNA testing to identify BRCA-mutated (BRCA+) patients in the MAGNITUDE study
Presenter: Gerhardt Attard
Session: Poster session 11
1649P - Impact of concomitant medications on safety in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) receiving rezvilutamide (Rez) plus androgen-deprivation therapy (ADT): A post-hoc analysis of the randomized phase III CHART trial
Presenter: Dingwei Ye
Session: Poster session 11
1650P - Fuzuloparib plus abiraterone acetate and prednisone (AA-P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase I study
Presenter: Tao Dai
Session: Poster session 11
1651P - Characteristics, tolerance and effectiveness of patients aged more or less than 75 years treated with [177Lu]Lu-PSMA-617 as part of France’s early access program
Presenter: David Tonnelet
Session: Poster session 11
1652P - SAABR: Single arm phase II study of androgen receptor pathway inhibitor (ARPI) + atezolizumab + GnRH analog (ADT) and stereotactic body radiotherapy (SBRT) to the prostate in men with de novo hormone-sensitive metastatic prostate cancer (mHSPC)
Presenter: Dana Rathkopf
Session: Poster session 11
1653P - Molecular and immunologic correlates of high PSMA/FOLH1 mRNA expression in prostate cancer (PC)
Presenter: Rana McKay
Session: Poster session 11
1654P - TAMARACK: Randomized Phase II trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Johann de Bono
Session: Poster session 11
1655P - Association of location of BRCA1/2 pathogenic variants with benefit from PARP-inhibitors in metastatic castration-resistant prostate cancers: Results from the PROGRESS study
Presenter: Lorena Incorvaia
Session: Poster session 11